Yeah, it's a little confusing. I'm with you @SaltyInvestor.
But the AFR seems to like it, annoucing "CSL increases dividend, flags profit growth in FY21".
When I look at the current years results, they have missed NPAT guidance by $7 million ($2,103M) but on a constant currency basis, the NPAT is $2,247M.
The outlook for FY2021 is a range. It could be flat, but it could be up by as much as 8%. This factors in new costs of R&D for a COVID vaccine and 4 COVID treatments, as well as global economic uncertainty.
Really, an extremely good result for 2020, and going forward for 2021, given we are in the depths of a global pandemic and the worst global recession since the Great Depression.
Yeah, it's a little confusing. I'm with you @SaltyInvestor.But...
-
- There are more pages in this discussion • 105 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$298.68 |
Change
-10.250(3.32%) |
Mkt cap ! $144.7B | |||
| Open | High | Low | Value | Volume |
| $300.03 | $301.28 | $298.51 | $90.72M | 302.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 39 | $298.67 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $298.68 | 231 | 3 |
View Market Depth
| Last trade - 10.58am 13/08/2024 (20 minute delay) ? |
| CSL (ASX) Chart |